Drug combinations
US6500827B2 · kind B2 · utility
0Cited by
7References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 11, 2001 |
| Grant date | Dec 31, 2002 |
| Priority date | — |
| Expiry date | Sep 5, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/535
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.